Chitosan-centered nanosystems as sustained therapeutics for allergic rhinitis intervention: Inhibition of histamine-induced cascades

Sun, Mengjie; Qin, Di; Fan, Peng-Sheng; Chen, Xiguang; Liu, Ya

doi:10.1016/j.jconrel.2021.05.048

Cited by 20 publications

(20 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The representative characteristics of AR significantly increased the recruitment and infiltration of inflammatory cells such as eosinophils and mast cells in the nasal mucosa . Histopathological analysis in the nasal cavity was further investigated to evaluate the therapeutic effect of SPIN-1, SPIN-2, and cetirizine.…”

Section: Resultsmentioning

confidence: 99%

“…The representative charac-teristics of AR significantly increased the recruitment and infiltration of inflammatory cells such as eosinophils and mast cells in the nasal mucosa. 30 Histopathological analysis in the nasal cavity was further investigated to evaluate the therapeutic effect of SPIN-1, SPIN-2, and cetirizine. All of the mice were sacrificed on day 34 to harvest the nasal cavity samples, which were stained with H&E and toluidine blue, and were observed under a light microscope.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis

Ding

Liang

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Allergic rhinitis (AR) is a chronic inflammatory reaction by immunoglobulin E (IgE) mediators after individual contact with allergens. It affects 10–40% of the world’s population and reduces the quality of life. Long-term symptoms of rhinitis can cause inflammation to spread and trigger asthma, which can harm human health. Herein, we develop a Smart PeptIde defeNse (SPIN) web technique, which in situ constructs a peptide web, trapping IgE against AR. Two candidate SPINs, SPIN-1 and SPIN-2, are designed with different IgE-binding sequences. The SPIN-1 or SPIN-2 is able to bind to IgE and transform from nanoparticles into entangled nanofibers. In turn, the web of SPIN-1 or SPIN-2 acts as a long-term trap of IgE to prevent the IgE from binding to mast cells. SPIN-1 or SPIN-2 (10 mg/kg) is able to treat AR model Balb/c mice with high efficiency and reduced symptoms of rhinitis and inflammatory factors, even better than a first-line clinical drug, cetirizine (10 mg/kg). For example, the amount of IL-4 released in the AR group (185.5 ± 6.8 pg/mL) is significantly reduced after the treatment with SPIN-1 (70.4 ± 14.1 pg/mL), SPIN-2 (86.0 ± 9.3 pg/mL), or cetirizine (112.8 ± 19.3 pg/mL). More importantly, compared with the cetirizine group (1 day), the SPIN-1 or SPIN-2 group shows long-term therapeutic effects (1 week). The SPIN web technique shows the great potential for blocking IgE binding to mast cells in vivo, attenuating AR or other allergic reactions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis

Ding

Liang

et al. 2022

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

show abstract

“…(d) Mechanism of action for hydroxybutyl chitosan NPs decorated with cetirizine and containing ketotifen (KT, red stars) inhibiting histamine release from mast cells. Reproduced with permission from ref . Copyright 2021 Elsevier B.V.…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

“…A popular condition in literature is allergic rhinitis, which is characterized by upper airway inflammation, sneezing, and itching . These symptoms typically result in poor retention and limited uptake of free therapeutics . Accordingly, mucoadhesive nanoparticles have improved treatment outcomes by enhancing retention in the nasal mucosa. , For example, chitosan-based mucoadhesive nanoparticles facilitated antiallergy effectiveness (near control levels of histamine, TNF-α, IL-4 and 5) at reduced treatment frequency (every 4 d) compared to free drug by combining antihistamine drug release with histamine receptor agonist-functionalized chitosan (Figure d) .…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Watchorn

Clasky

Prakash

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in the human body. High vascularization and accessibility have motivated drug delivery to various mucosal surfaces; however, these benefits are hindered by the mucus layer. To overcome the mucus barrier, many nanomedicines have been developed, with the goal of improving the efficacy and bioavailability of drug payloads. Two major nanoparticle-based strategies have emerged to facilitate mucosal drug delivery, namely, mucoadhesion and mucopenetration. Generally, mucoadhesive nanoparticles promote interactions with mucus for immobilization and sustained drug release, whereas mucopenetrating nanoparticles diffuse through the mucus and enhance drug uptake. The choice of strategy depends on many factors pertaining to the structural and compositional characteristics of the target mucus and mucosa. While there have been promising results in preclinical studies, mucus−nanoparticle interactions remain poorly understood, thus limiting effective clinical translation. This article reviews nanomedicines designed with mucoadhesive or mucopenetrating properties for mucosal delivery, explores the influence of site-dependent physiological variation among mucosal surfaces on efficacy, transport, and bioavailability, and discusses the techniques and models used to investigate mucus−nanoparticle interactions. The effects of non-homeostatic perturbations on protein corona formation, mucus composition, and nanoparticle performance are discussed in the context of mucosal delivery. The complexity of the mucosal barrier necessitates consideration of the interplay between nanoparticle design, tissue-specific differences in mucus structure and composition, and homeostatic or disease-related changes to the mucus barrier to develop effective nanomedicines for mucosal delivery.

show abstract

“…The possibility of the co-delivery of more than one drug represents an obvious advantage of nanocarriers. Hydroxyl chitosan nanoparticles loaded with ketotifen (histamine release inhibitor) and decorated with cetirizine (histamine receptor antagonist) for the treatment of allergy reduced the treatment frequency to every 4 days and the dose to 50% in rats [ 115 ].…”

Section: Overcoming Non-cellular Barriersmentioning

confidence: 99%

Non-Cellular Layers of the Respiratory Tract: Protection against Pathogens and Target for Drug Delivery

Frőhlich

2022

Pharmaceutics

View full text Add to dashboard Cite

Epithelial barriers separate the human body from the environment to maintain homeostasis. Compared to the skin and gastrointestinal tract, the respiratory barrier is the thinnest and least protective. The properties of the epithelial cells (height, number of layers, intercellular junctions) and non-cellular layers, mucus in the conducting airways and surfactant in the respiratory parts determine the permeability of the barrier. The review focuses on the non-cellular layers and describes the architecture of the mucus and surfactant followed by interaction with gases and pathogens. While the penetration of gases into the respiratory tract is mainly determined by their hydrophobicity, pathogens use different mechanisms to invade the respiratory tract. Often, the combination of mucus adhesion and subsequent permeation of the mucus mesh is used. Similar mechanisms are also employed to improve drug delivery across the respiratory barrier. Depending on the payload and target region, various mucus-targeting delivery systems have been developed. It appears that the mucus-targeting strategy has to be selected according to the planned application.

show abstract

Chitosan-centered nanosystems as sustained therapeutics for allergic rhinitis intervention: Inhibition of histamine-induced cascades

Cited by 20 publications

References 97 publications

Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis

Smart Peptide Defense Web In Situ Connects for Continuous Interception of IgE against Allergic Rhinitis

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Non-Cellular Layers of the Respiratory Tract: Protection against Pathogens and Target for Drug Delivery

Contact Info

Product

Resources

About